| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7c27b9ec61781656e6f039702fd568 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate |
2011-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1967e22eee9c4ec5d2207423d187abfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7289d1ded56dfb53799f935522456d95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aabff2371c5845a830de59d41e4a0223
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eb13f7e8d75bd2afa70a73d5f117e25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d614c0aead9d8db1d41f8522462acbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56b1127920ff16a0b84839f12b6f5776
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f355c8faa2707df1e3901f27b8f7f4f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_464f800b77eb19b5d476794935add3a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec94118bdcfdc4ec3733fafe44596dc7 |
| publicationDate |
2012-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120111347-A |
| titleOfInvention |
Arylsulfonamide derivatives having a cyclopropyl group, pharmaceutically acceptable salts thereof, and methods for preparing the same |
| abstract |
The present invention provides an arylsulfonamide derivative having a cyclopropyl group represented by the following formula (1) or a pharmaceutically acceptable salt thereof. Aryl sulfonamide derivatives are useful in the treatment of 11 beta-hydroxy steroid dehydrogenase various diseases by suppressing the now (11 -hydroxystreroid dehydrogenase type1 β, 11 β -HSD1) activity of a type 1, mediated by the 11 β -HSD1 Do. Formula 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101456628-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104628615-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104628617-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013019091-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104628617-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013019091-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101409847-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9073830-B2 |
| priorityDate |
2011-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |